Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This trial is designed as a multicenter, double-blinded, randomized, placebo controlled study to assess the safety and efficacy of JBM-TC4 for the prevention and treatment of acute radiation-induced dermatitis in breast cancer patients receiving radiotherapy.
Epistemonikos ID: 0b10c92266e81f15aff20eb9a3cafb0790597f63
First added on: May 12, 2024